Compare Charles Schwab Corporation Common Stock (SCHW) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles Schwab Corporation Common Stock vs Zimmer Biomet Holdings Inc — how do they compare? Charles Schwab Corporation Common Stock trades at $100.2 (market cap $178.33B), while Zimmer Biomet Holdings Inc trades at $90.03 (market cap $17.36B). The key difference: Charles Schwab Corporation Common Stock is far larger — about 10.3× Zimmer Biomet Holdings Inc's market cap, and Charles Schwab Corporation Common Stock pays the higher dividend (1.25%). Which is the better fit depends on your goals.
| SCHW | ZBH | |
|---|---|---|
Market Cap | $178.33B | $17.36B |
Sector | Financials | Health |
52-Week High | $107.21 | $107.71 |
52-Week Low | $85.35 | $79.58 |
Dividend Yield | 1.25% | 1.07% |
Enterprise Value | — | $24.40B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
